Protein arginine methyltransferase-5 (PRMT5) is involved in tumorigenesis and is upregulated in several malignancies including breast cancer, colorectal cancer, lung cancer, and lymphoma. Symmetric dimethyl arginine (SDMA) is formed by the catalytic activity of type 2 protein arginine methyltransferases. SDMA may be a useful biomarker for PRMT5 inhibitors.